Other languages Johnson & Johnson Wiener Boerse

Equities

JNJ

US4781601046

Real-time Estimate Tradegate Other stock markets 04:40:23 2024-07-01 EDT			5-day change	1st Jan Change
136.2 ^EUR	-0.49%		-1.43%	-3.39%

06-28	Johnson & Johnson Reports 'Positive' Results in Late-Stage Myasthenia Gravis Trial	MT
06-28	J&J Unit's Rybrevant Combo Gets EU Approval	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Momentum Picks T3 2024 : 5 actions pour l'été	03:43am
En Direct des Marchés : Thales, Airbus, Sanofi, Stellantis, Atos, Valneva, Boeing...	02:24am
Nouveau semestre, nouvel état d'esprit	02:12am
Bolsa de Madrid: Un nuevo semestre, un nuevo estado de ánimo	02:00am
Johnson & Johnson Reports 'Positive' Results in Late-Stage Myasthenia Gravis Trial	06-28
J&J Unit's Rybrevant Combo Gets EU Approval	06-28
Johnson & Johnson Announces Positive Results from the Nipocalimab Phase 3 Vivacity-MG3 Study	06-28
Johnson & Johnson's Balversa Gets EU Panel Recommendation for Urothelial Carcinoma	06-28
Dealmakers optimistic on global M&A prospects despite sluggish growth	06-28
US FDA declines to approve Merck-Daiichi's 'guided missile' cancer drug	06-27
US Supreme Court gives pharma companies a chance to thwart terrorism-funding lawsuit	06-24
J&J : 50M d'élèves aidés via le programme 'Sight for Kids'	06-24
Sector Update: Health Care Stocks Edge Up in Afternoon Trading	06-21
Johnson & Johnson : dossier déposé dans la maladie de Crohn	06-21
Johnson & Johnson : le rachat de Proteologix est bouclé	06-21
Johnson & Johnson Completes Acquisition of Proteologix	06-21
Johnson & Johnson Completes Acquisition of Proteologix	06-21
Johnson & Johnson completed the acquisition of Proteologix, Inc. from Pharmaron Beijing Co., Ltd and other shareholders for approximately $850 million.	06-20
Johnson & Johnson Files Application With US FDA Seeking Approval of Tremfya to Treat Crohn's Disease	06-20
Johnson & Johnson Submits Application to U.S. FDA Seek Approval of TREMFYA®? for the Treatment of Moderate to Severe Active Crohn's Disease	06-20

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Joseph Wolk, CFO of J&J: End of patent for its flagship drug

January 23, 2024 at 12:30 pm